Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...

According to Vertex Pharmaceuticals, approximately 300 additional ... 6 years and older with at least 1 qualifying non-F508del Trikafta-responsive mutation and with no exclusionary mutation.

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43rd ...

Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...

Ratings for Vertex Pharmaceuticals (NASDAQ ... Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally.